Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeff Alder

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 12, 2005
The clinical relevance and correct designation of isolates nonsusceptible to daptomycinJeff Alder, Barry I Eisenstein
Antimicrobial Agents and Chemotherapy|April 24, 2003
Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureusGeorge Sakoulas, George M Eliopoulos, Jeff Alder, et al.
BMJ Open Respiratory Research|December 22, 2015
Ciprofloxacin DPI: a randomised, placebo-controlled, phase IIb efficacy and safety study on cystic fibrosisHenry L Dorkin, Doris Staab, Elisabeth Operschall, et al.
The Journal of Antimicrobial Chemotherapy|February 12, 2005
Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infectionsJudith N Steenbergen, Jeff Alder, Grace M Thorne, et al.
Antimicrobial Agents and Chemotherapy|March 30, 2006
Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycinGeorge Sakoulas, Jeff Alder, Claudie Thauvin-Eliopoulos, et al.
Diagnostic Microbiology and Infectious Disease|August 11, 2017
In Vitro activities of Tedizolid and comparator antimicrobial agents against clinical isolates of Staphylococcus aureus collected in 12 countries from 2014 to 2016James A Karlowsky, Meredith A Hackel, Samuel K Bouchillon, et al.
The Journal of Infectious Diseases|May 18, 2005
Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impactJared A Silverman, Lawrence I Mortin, Andrew D G Vanpraagh, et al.
The European Respiratory Journal|December 3, 2011
Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL resultsRobert Wilson, Antonio Anzueto, Marc Miravitlles, et al.
Antimicrobial Agents and Chemotherapy|October 25, 2003
Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infectionJeff Alder, Tongchaun Li, Donghui Yu, et al.
Journal of Clinical Microbiology|November 16, 2007
Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycinGeorge Sakoulas, Warren Rose, Michael J Rybak, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 12, 2005
The clinical relevance and correct designation of isolates nonsusceptible to daptomycinJeff Alder, Barry I Eisenstein
Antimicrobial Agents and Chemotherapy|April 24, 2003
Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureusGeorge Sakoulas, George M Eliopoulos, Jeff Alder, et al.
BMJ Open Respiratory Research|December 22, 2015
Ciprofloxacin DPI: a randomised, placebo-controlled, phase IIb efficacy and safety study on cystic fibrosisHenry L Dorkin, Doris Staab, Elisabeth Operschall, et al.
The Journal of Antimicrobial Chemotherapy|February 12, 2005
Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infectionsJudith N Steenbergen, Jeff Alder, Grace M Thorne, et al.
Antimicrobial Agents and Chemotherapy|March 30, 2006
Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycinGeorge Sakoulas, Jeff Alder, Claudie Thauvin-Eliopoulos, et al.
Diagnostic Microbiology and Infectious Disease|August 11, 2017
In Vitro activities of Tedizolid and comparator antimicrobial agents against clinical isolates of Staphylococcus aureus collected in 12 countries from 2014 to 2016James A Karlowsky, Meredith A Hackel, Samuel K Bouchillon, et al.
The Journal of Infectious Diseases|May 18, 2005
Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impactJared A Silverman, Lawrence I Mortin, Andrew D G Vanpraagh, et al.
The European Respiratory Journal|December 3, 2011
Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL resultsRobert Wilson, Antonio Anzueto, Marc Miravitlles, et al.
Antimicrobial Agents and Chemotherapy|October 25, 2003
Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infectionJeff Alder, Tongchaun Li, Donghui Yu, et al.
Journal of Clinical Microbiology|November 16, 2007
Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycinGeorge Sakoulas, Warren Rose, Michael J Rybak, et al.
Pageof 3